"We believe that positive data anticipated from the proposed phase I trial along with success in its efficacy studies in animals will provide BioCryst with the necessary data for Peramivir to become eligible for government stockpiling," analyst Vinny Jindal of Wedbush Morgan wrote in a recent research report.
According to Jindal, BioCryst has a chance to have one of three major avian flu drugs with Peramivir. The others are Tamiflu, marketed by Gilead (GILD) and Roche, and Relenza, sold by Australia's Biota and GlaxoSmithKline (GSK) of the U.K.
Wedbush Morgan does and seeks to do business with companies covered in its research reports.
Until recently, large pharmaceutical companies lived by a business model focused on marketing prowess and patent protection, according to Brozak. Now, companies like Roche are beginning to focus on understanding technology and acquiring novel developmental drugs.